8
total announcements
SPARC.NS · 15 min delayed
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange about Copy of Newspaper Publication related to the 21st Annual General Meeting of the Company and other related information.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 10, 2026 along with the Annual Report for FY 2025-26.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Change in Director(s) of the company. Dr. Rajamannar Thennati retires from the Board of Directors upon completion of his term, and Mr. Anil Raghavan is appointed as Managing Director and Chief Executive Officer with effect from August 11, 2026.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange about the publication of a newspaper advertisement regarding the 21st Annual General Meeting of the Company and other related information. The company has recommended a final dividend of 7.3 per equity share of face value of ₹ 5 each (i.e. 60 percent) for the financial year 2025-2026.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding the 21st Annual General Meeting of the Company, to be held on August 10, 2026, through Video Conference/OAVM, with the Annual Report and Notice available on the company's website.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has received a confirmation certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026, indicating that securities received for dematerialization were confirmed and listed on stock exchanges.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange about change in Management, with Ms. Shanta Gupta and Dr. Nitin Dharmadhikari retiring and Mr. Prasanna Deshmukh appointed as Functional Head – Human Resources & Administration.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange about the termination of a license agreement with CMS Bridging DMCC. The agreement was for the development and commercialization of multiple products in Mainland China, Hong Kong, Macao, and Taiwan. The termination has no material impact on the company's financial position, operations, or other activities.